Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Intestine Cancer Therapeutics Industry Expected To Reach By 2029, Starting From 2025 Levels?
The intestine cancer therapeutics market has demonstrated substantial growth in recent years. This market is anticipated to expand from $14 billion in 2024 to $15.12 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.0%. Historically, this expansion has been driven by advancements in medical research, an increase in cancer incidence, the application of chemotherapy and radiation therapies, initiatives for screening and early detection, and discoveries in genetics and biomarkers.
The intestine cancer therapeutics market is anticipated to demonstrate robust expansion in the near future. Its value is set to reach $20.88 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.4%. Factors contributing to its growth throughout the forecast period encompass advancements in immunotherapy, tailored precision medicine and personalized therapies, the introduction of novel targeted therapies, the application of artificial intelligence (AI), and patient-centered methodologies. Prominent trends expected over the forecast horizon comprise liquid biopsy technologies, advances in precision medicine and biomarker exploration, the rise of combination therapies, an emphasis on patient-centric care alongside supportive treatments, and the increasing preference for minimally invasive surgical techniques.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13231&type=smp
What Are The Key Drivers Of Growth In The Intestine Cancer Therapeutics Market?
The escalating occurrence of hereditary colorectal cancer syndromes is anticipated to significantly advance the intestine cancer therapeutics market. These syndromes are defined as a collection of genetic conditions that elevate an individual’s susceptibility to developing colorectal cancer, encompassing cancer of the colon or rectum. They play a vital role in the field of intestinal cancer therapeutics by furnishing crucial information linked to specific genetic mutations that considerably heighten the danger of colorectal cancer development. For instance, data from July 2023, provided by the World Health Organization, an intergovernmental organization based in Switzerland, indicates that by 2040, the prevalence of hereditary colorectal cancer is projected to rise substantially, with an estimated 3.2 million new cases and 1.6 million deaths occurring each year. This represents a 63% increase in new cases and a 73% increase in fatalities when compared to current figures. Consequently, the increasing prevalence of hereditary colorectal cancer syndromes is a primary driver for the expansion of the intestine cancer therapeutics market.
What Are The Major Segment Categories Driving The Intestine Cancer Therapeutics Market Growth?
The intestine cancer therapeuticsmarket covered in this report is segmented –
1) By Treatment Type: Immunotherapy; Chemotherapy; Other Treatments
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
3) By Application: Hospitals; Homecare; Specialty Centers; Other Applications
Subsegments:
1) By Immunotherapy: Checkpoint Inhibitors; CAR T-Cell Therapy; Cancer Vaccines
2) By Chemotherapy: Adjuvant Chemotherapy; Neoadjuvant Chemotherapy; Palliative Chemotherapy
3) By Other Treatments: Targeted Therapy; Radiation Therapy; Surgery; Hormone Therapy
Which Key Trends Are Expected To Influence The Intestine Cancer Therapeutics Market In The Coming Years?
Leading firms within the intestine cancer therapeutics market are creating groundbreaking products like Lonsurf and securing regulatory approvals to reach broader customer segments, enhance sales, and boost revenue. LONSURF comprises a dual drug formulation of trifluridine and tipiracil, intended for the treatment of adult individuals suffering from metastatic colorectal cancer. As an illustration, in August 2023, Taiho Oncology Inc., a pharmaceutical firm based in the US, obtained approval for Lonsurf from the US Food and Drug Administration. Lonsurf is offered in the form of a solitary oral tablet. Trifluridine functions by inhibiting cancer cell proliferation, whereas tipiracil aids trifluridine’s prolonged efficacy by hindering its degradation within the body. The authorization of Lonsurf offers patients with metastatic colorectal cancer and other qualifying cancers access to a novel therapeutic choice that holds the potential to enhance treatment results and overall life quality.
Who Are The Primary Competitors In The Global Intestine Cancer Therapeutics Market?
Major companies operating in the intestine cancer therapeutics market report are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report
How Does The Intestine Cancer Therapeutics Market Perform Across Key Geographic Regions?
Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Intestine Cancer Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13231&type=smp
Browse Through More Reports Similar to the Global Intestine Cancer Therapeutics Market 2025, By The Business Research Company
Anti Inflammatory Therapeutics Global Market Report 2025
Small Cell Lung Cancer Therapeutics Global Market Report 2025
Duchenne Muscular Dystrophy Dmd Therapeutics Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model